Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 8/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446008 | 0.92 | PSMB1 (0.49) | PSMB1PSMB5PSMB2LTA4HESR1 | |
| SCHEMBL1445639 | 0.85 | PDE3A (0.49) | TSHR | |
| SCHEMBL1445700 | 0.83 | ALDH1A1 (0.48) | LTA4HHRH3 | |
| SCHEMBL1445802 | 0.81 | HRH3 (0.45) | LTA4HHRH3AGERTSHR | |
| SCHEMBL1446614 | 0.80 | PDE10A (0.60) | TSHR | |
| SCHEMBL1445816 | 0.79 | LTA4H (0.63) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL876980 | 0.78 | LTA4H (0.75) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL1445898 | 0.77 | PDE3A (0.49) | TSHR | |
| SCHEMBL1446553 | 0.76 | HRH3 (0.64) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL12176949 | 0.76 | HRH3 (0.46) | ESR1ESR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7897387-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT, LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT, LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT, LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-7375204-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375204-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375204-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060234283-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20060234349-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20040038239-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038239-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | PSMB1 2426/4885PSMB5 1844/4885PSMB2 2871/4885 |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | ERG28, GPI, DPM1 | PSMB1 2145/4885PSMB5 1508/4885PSMB2 2560/4885 |
| US-20060234349-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | PSMB1 2426/4885PSMB5 1844/4885PSMB2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.